Showing results (51-60 of 66) with videos related to
Sort By:
Pageof 7
Hematological Oncology|April 13, 2025
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14-Year Experience of an Academic CenterDanai Dima, Utkarsh Goel, Fauzia Ullah, et al.Plos One|March 10, 2017
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosisSurbhi Sidana, Mayur Narkhede, Paul Elson, et al.Cancers|May 27, 2026
Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early TherapyKirti Arora, Lara Soueid, Louis Williams, et al.Mayo Clinic Proceedings|July 14, 2006
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myelomaMohamad A Hussein, Rachid Baz, Gordan Srkalovic, et al.Journal of Clinical Medicine|September 9, 2023
Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused ReviewRazwana Khanam, Beth Faiman, Saba Batool, et al.Cancer Research Communications|June 3, 2026
Multiple Myeloma Screening Education: A Community-Based Health Literacy InterventionKarie Feldman, Hong Li, Diana Basali, et al.British Journal of Haematology|May 17, 2021
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort studyFahrettin Covut, Ramsha Ahmed, Sanchit Chawla, et al.Mayo Clinic Proceedings|December 14, 2005
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myelomaRachid Baz, Liang Li, Kandice Kottke-Marchant, et al.Patient Preference and Adherence|October 24, 2024
Patient, Care Partner, and Physician Voices in Treatment Decision-Making for Multiple MyelomaLisa Dwyer Orr, Dee Lin, Bingcao Wu, et al.Journal of Hematology & Oncology|August 17, 2022
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutationMuhammad Elnaggar, Sarita Agte, Paula Restrepo, et al.Pageof 7